Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2004

View Archived Issues

NQOI inducer dimethylfumarate boosts mitomycin C antitumor activity in vivo

Add-on Uvadex therapy reported to improve outcome in patients receiving ASCT

New data on the benefits of omega-3 fatty acid supplementation in chronic epilepsy

DURIN leuprolide acetate IND accepted

NG2-73 enters clinical testing for insomnia

Dopamine reuptake inhibitor NS-2330 ineffective as a treatment for advanced Parkinson's disease

Inhibition of poly(ADP-ribose) synthase increases cardiac allograft survival

Approval for rhC1INH IND application

WinRho SDF completes European mutual recognition procedure

PRX-03140 enters phase I for Alzheimer's

Enrollment open in new phase II study of INO-1001

Monoclonal antibody may restore tamoxifen responsiveness in resistant human breast cancer cells

GTC submits responses regarding ATryn MAA

RegeneRx seeks to begin new phase II study of TB4 for venous stasis ulcers

MethylGene initiates phase I HDAC cancer study in hematological malignancies

European CHMP recommends approval of Aloxi

Encouraging data for HuMax-Inflam/MDX-018 in autoimmune study

Novel ribonuclease immunotoxin shows potent immunotoxicity in vivo

New head-to-head study compares Tysabri to Rebif

Rigel initiates phase I study of R-406

Concern over cardiovascular risk of naproxen

Genzyme completes acquisition of Ilex Oncology

sNDA filing for Attenace for ADHD

Arena forms diabetes collaboration with Ortho-McNeil

Cell Therapeutics enters Trisenox financing deal

New phase IIa study for ATL-1102 in MS

Nabi seeks European approval for StaphVAX

CB1 receptor antagonists described by Pfizer

Two series of Tie-2 modulators claimed by Exelixis

Glutamate receptor modulators described in patent literature

Scientists at Millennium claim beta-carboline compounds

Novel antibacterial carbapenems prepared and tested at Sumitomo

ChondroGene and Pfizer enter new osteoarthritis collaboration

Popular Stories

Today's news in brief
BioWorld
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...